Definium Therapeutics (DFTX)
NASDAQ:DFTX
Want to see DFTX full AI Analyst Report?
DFTX Stock Chart & Stats
$22.68
-$0.97(-11.96%)
At close: 4:00 PM EST
$22.68
-$0.97(-11.96%)
Day’s Range― - ―
52-Week Range$6.03 - $26.25
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.68M
Market Cap
$2.40B
Enterprise Value$2.14B
Total Cash (Recent Filing)$373.42M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.59
Next Earnings
Aug 13, 2026EPS Estimate
-0.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.50
Shares Outstanding109,066,780
10 Day Avg. Volume1,652,482
30 Day Avg. Volume1,678,551
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)3.60
Price to Sales (P/S)0.00
P/FCF Ratio-9.09
Enterprise Value/Market Cap0.89
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-10.38
Forecast
1Y Price Target
$40.00Price Target Upside76.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-2
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial ReadoutsTopline results from late-stage Phase III trials of DT120 in generalized anxiety disorder and major depressive disorder will directly influence the company's regulatory trajectory and valuation potential.
Market Opportunity And PrevalenceIncreasing diagnosed prevalence of generalized anxiety disorder and a large untreated patient population create a significant commercial opportunity for DT120 if approved and successfully reimbursed.
Safety Profile And KOL SupportA relatively benign safety profile for DT120 combined with favorable feedback from key opinion leaders could reduce adoption barriers and support clinician confidence if efficacy is confirmed.
Bears Say
Financing And Cash RunwayHigh cash burn to support multiple late-stage trials raises financing risk and could necessitate capital raises that dilute existing shareholders before commercialization generates revenue.
Regulatory And Controlled Substance RiskDT120's relation to a tightly controlled substance introduces additional regulatory scrutiny and potential approval challenges that could complicate development and market access.
Treatment Delivery ConstraintsLengthy in-clinic treatment sessions required for DT120 could restrict patient throughput at clinics and limit broad commercial adoption despite positive clinical data.
Definium Therapeutics News
DFTX FAQ
What was Definium Therapeutics’s price range in the past 12 months?
Definium Therapeutics lowest stock price was $6.03 and its highest was $26.25 in the past 12 months.
What is Definium Therapeutics’s market cap?
Definium Therapeutics’s market cap is $2.40B.
When is Definium Therapeutics’s upcoming earnings report date?
Definium Therapeutics’s upcoming earnings report date is Aug 13, 2026 which is in 96 days.
How were Definium Therapeutics’s earnings last quarter?
Definium Therapeutics released its earnings results on May 07, 2026. The company reported -$0.71 earnings per share for the quarter, missing the consensus estimate of -$0.492 by -$0.218.
Is Definium Therapeutics overvalued?
According to Wall Street analysts Definium Therapeutics’s price is currently Undervalued.
Does Definium Therapeutics pay dividends?
Definium Therapeutics does not currently pay dividends.
What is Definium Therapeutics’s EPS estimate?
Definium Therapeutics’s EPS estimate is -0.55.
How many shares outstanding does Definium Therapeutics have?
Definium Therapeutics has 109,066,780 shares outstanding.
What happened to Definium Therapeutics’s price movement after its last earnings report?
Definium Therapeutics reported an EPS of -$0.71 in its last earnings report, missing expectations of -$0.492. Following the earnings report the stock price went down -4.957%.
Which hedge fund is a major shareholder of Definium Therapeutics?
Currently, no hedge funds are holding shares in DFTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Definium Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$40.00 (76.37% Upside)
$40.00 (76.37% Upside)
Blogger Sentiment
Bullish
DFTX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 3.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.6%
Last 30 Days ▲ 10.8%
Last 30 Days ▲ 10.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
293.06%
12-Months-Change
Fundamentals
Return on Equity
-84.39%
Trailing 12-Months
Asset Growth
45.66%
Trailing 12-Months
Company Description
Definium Therapeutics
Definium Therapeutics, Inc. is a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
DFTX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasizes strong clinical momentum (multiple Phase III programs with imminent topline readouts, Breakthrough Therapy designation in GAD, high statistical power in key studies), a clear commercialization plan and a solid cash position ($373.4M runway into 2028). These positives are tempered by materially higher operating expenses and a sizable YOY increase in net loss (driven by program investment and a non-cash warrant valuation change), design-related placebo risk from Phase II, and remaining regulatory and payer uncertainties that could affect timing and labeling. On balance, management’s message is forward-looking and execution-focused with meaningful near-term inflection points.View all DFTX earnings summariesDFTX Stock 12 Month Forecast
Average Price Target
$40.00
▲(76.37% Upside)
Technical Analysis
AnaptysBio
―
Enliven Therapeutics
―
Tyra Bioscience
―
Biohaven Ltd.
―
Inhibrx Biosciences Inc
―
Ownership Overview
1.58% Insiders
5.12% Mutual Funds
1.75% Other Institutional Investors
82.64% Public Companies and Individual Investors